Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03952520
Other study ID # 18-2901
Secondary ID 1R01DA047876-01I
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 10, 2020
Est. completion date May 2024

Study information

Verified date May 2023
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare two implementation approaches [Standard Approach (SA) vs. Tailored Approach (TA)] for scaling-up the evidence-based systems navigation and psychosocial counseling integrated intervention (SNaP) in HIV test sites in Vietnam.


Description:

This is a cluster randomized, controlled implementation trial to compare two implementation approaches (standard and tailored) for scaling-up the SNaP intervention in 42 HIV test sites in Vietnam. The SNaP intervention combines systems navigation and psychosocial counseling for people who inject drugs (PWID), and it is designed to facilitate PWID's engagement in HIV and substance use care. The two implementation approaches being compared are: - Standard Approach (SA); vs. - Tailored Approach (TA) SNaP is an evidence-based intervention (EBI) that combines systems navigation and psychosocial counseling to facilitate the engagement of HIV-infected people who inject drugs (PWID) into HIV and substance use care. The 42 HIV test sites will be randomized in a 1:1 ratio to either the standard approach (SA) procedure or a tailored approach (TA). At the HIV test sites, the study will enroll: - A cohort of 630 PWID who are newly diagnosed or previously diagnosed but not on ART will be enrolled for detailed assessments, including follow-up surveys and dried blood spot collection for viral loads. Additional PWID may be enrolled for medical records assessment without recontact. An additional 242 clinic staff will be enrolled to assess implementation outcomes. - Note that the original design included ~6200 PWID attending the clinics who consented for medical record assessments only. Upon study initiation, the number of PWID with newly diagnosed HIV infection was substantially lower than predicted. The planned cohort sample was then reduced in size to 630 and all PWID meeting eligibility criteria were referred for enrollment in this cohort. - HIV test site director boards and staff. Study activities will span across 5 years, with approximately 27 months at each site and recruitment of PWID participants over 21 months. . For the cohort PWID or PWID selected for qualitative interviews, maximum study participation time is 24-27 months. For PWID with medical record assessment only, participation is a one-time visit. For HIV test site director boards and staff, maximum time in the study is 24-27 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 872
Est. completion date May 2024
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: PWID participants: 1. HIV infection: - Newly diagnosed HIV infection, based on confirmatory test, and not currently on ART at the time of study enrollment; or - If previously diagnosed with HIV infection, then must not currently be on ART at the time of study enrollment (self-reported) 2. Age 18 years or older 3. Injection drug use within the past 6 months (self-reported at time of screening) 4. Willing to provide informed consent for the study Test site director boards and staff: 1. All test site director boards and staff, including the navigators and counselors, at the selected HIV test sites 2. Willing to provide informed consent for the study Exclusion Criteria: PWID participants: 1. Residence outside of the catchment area of local antiretroviral therapy (ART) and medication-assisted treatment (MAT, e.g. methadone) clinics 2. Currently on ART at time of study enrollment (self-reported) 3. Planning to move out of the catchment area within the next 24 months.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Standard Approach (SA)
The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
Tailored Approach (TA)
The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.

Locations

Country Name City State
Vietnam Hanoi Medical University Hanoi

Sponsors (6)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Hanoi Medical University, Johns Hopkins University, National Institute on Drug Abuse (NIDA), Ohio State University, Vietnam Administration for HIV/AIDS Control (VAAC)

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fidelity to SNaP Intervention Procedures Fidelity measures whether the SNaP intervention was delivered as intended.
Fidelity score = (% Systems navigation sessions completed x Average navigation session quality score) + (% Counseling sessions completed x Average counseling session quality score)
Session completion will be assessed by reviewing the navigator and counselor logs, while session quality will be assessed by central implementation team review and scoring of a random 10% of all forms (navigation) and audio-recordings (psychosocial counseling).
Test site fidelity score range: 0-200 (Higher score indicates higher fidelity.)
measured over 26 months after SNaP implementation in a clinic
Primary % PWID Who Initiated ART % of PWID who initiated ART among the PWID who initiated SNaP, measured through ART clinic records of consenting PWID and/or self-report.
This measures ART uptake among PWID who initiated the SNaP intervention.
Medical record reviews conducted within 6 months after enrollment; self-report: 6-12 months after enrollment among those who initiated SNaP
Secondary % PWID Who Were Contacted and Participated in SNaP Penetration of SNaP at the test sites is assessed by this measure.
Penetration of SNaP is defined as the proportion of newly diagnosed or previously diagnosed and not currently on ART PWID at test sites who are contacted by a navigator and/or counselor and participate in a SNaP session.
Penetration of SNaP will be assessed at 12 and 24 months after implementation of SNaP in a clinic.
Up to 24 months after implementation of SNaP in a clinic
Secondary Acceptability of SNaP by PWID Acceptability is the perception that the SNaP intervention is agreeable, palatable, or satisfactory to PWID.
Acceptability among PWID participants will be assessed using the Acceptability of Intervention Measure (AIM), which consists of 4 items containing responses on a 5-point Likert scale. The AIM score will be the sum of the 4 item responses. Higher AIM scores indicate higher acceptability.
Acceptability of SNaP by PWID will be assessed at 12, 18, and 24 months after SNaP implementation in a clinic.
Up to 24 months after SNap implementation in a clinic.
Secondary Acceptability of SNaP by Test Site Staff Acceptability is the perception that the SNaP intervention is agreeable, palatable, or satisfactory to test site staff.
Acceptability among site staff will be assessed using the Ottawa Acceptability of Decision Rules Instrument (OADRI), a 12-item scale, staff and client acceptability of an innovation in a clinic setting. Eight of the 12 items were included in the assessment, excluding 4 irrelevant questions for the study setting. Higher OADRI scores indicate higher acceptability.
Acceptability of SNaP by Test Site Staff will be assessed at 12 and 24 months after SNaP implementation in a clinic.
Up to 24 months after implementation of SNaP in a clinic
Secondary % PWID Who Are Virally Suppressed % of PWID who are virally suppressed among the PWID who initiated SNaP
Viral suppression is defined as <1000 copies/mL. (This outcome will be measured only in the PWID subsample cohort.)
% of PWID who are virally suppressed will be assessed at 12, 18, and 24 months after SNaP implementation in a clinic.
Up to 24 months after implementation of SNaP in a clinic.
Secondary % PWID on Medication-Assisted Treatment (MAT) % of PWID alive and on MAT among the PWID who initiated SNaP, measured through medical records and/or self-report of consenting PWID.
This measures MAT uptake among PWID who initiated SNaP.
% of PWID on MAT will be assessed at 12, 18, and 24 months after SNaP implementation in a clinic.
Up to 24 months after SNaP implementation in a clinic
Secondary Incremental Cost-Effectiveness Ratio of SA Compared to TA for SNaP Implementation The incremental cost per incremental ART uptake, comparing TA to SA, measured as: The difference in costs of implementing SNaP in TA compared to SA sites divided by the difference in ART uptake in TA compared to SA sites.
Incremental cost-effectiveness of SNaP implementation will be assessed up to 24 months after SNaP implementation in a clinic.
Up to 24 months after SNaP implementation in a clinic.
Secondary % of PWID alive and remaining on ART of PWID alive and on ART among the PWID who initiated SNaP, measured through medical records and/or self-report of consenting PWID
of PWID alive and remaining on ART will be assessed at 12, 18, and 24 months after SNaP implementation in a clinic.
Up to 24 months after SNaP implementation in a clinic.
Secondary % of clinics continuing to offer SNaP after completion of study activities Sustainment of SNaP at the test sites is assessed by this measure.
Sustainment of SNaP is defined as the % of clinics continuing to offer SNaP after completion of study activities, based on survey of clinic staff
Sustainment of SNaP will be assessed up to 37 months after SNaP implementation in a clinic.
Up to 37 months after SNaP implementation in a clinic
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2